Abstract:Heart failure (HF) affects millions of people around the world and is a prevalent health issue in the United States. In many cases, HF has an intricate connection with mitral valvular disease (MVD), which can alter a patient's disease course. Factors such as gender, race, ethnicity, and social determinants of health impact the prevalence, etiology, and treatment of MVD associated with HF. This literature review examines the connection between MVD and HF among adult patients, considering MVD as both a cause and an outcome of HF. This article also identifies the differences in epidemiology and treatment of MVD associated with HF across different gender, ethnicity, race, and socioeconomic groups. This is in an effort to not only identify currently overlooked disparities but to highlight potential ways to improve them. MVD was analyzed based on its hemodynamic subtypes, mitral regurgitation (MR) and mitral stenosis (MS), as these subtypes encompass different etiologies of MVD. The purpose of this article was to identify broad disparities in MVD in association with HF in the adult population. The results of this study found stark differences between prevalence, treatment, and disease outcomes across groups. Women and Black patients were identified as high-risk for under-utilization and prescription delay of treatment options. Women were often treated at more advanced stages of MVD, while treatment was often delayed in Black patient populations. Factors such as these impact treatment outcomes. Conversely, men and White patients were identified as lower-risk groups for treatment inadequacies and poor HF and MVD related outcomes. Socioeconomic status (SES) was also found to play a role, with low SES being a risk factor for developing rheumatic heart disease. Low SES groups are also more likely to develop HF, which predisposes to secondary MR. Despite general knowledge of these disparities, few studies analyze HF and MVD for specific groups. This literature review is thus necessary to identify current inequities in care and underscore potential solutions to raise awareness for further research efforts and funding. This analysis identifies MVD treatment guidelines and contributing social determinants of health as areas that must be addressed to minimize HF and MVD disparities.

Unmet needs in valvular heart disease

Burden of Valvular Heart Disease, 1990-2017: Results from the Global Burden of Disease Study 2017.

The future of valvular heart disease assessment and therapy

Global epidemiology of valvular heart disease

Valvular heart disease: from mechanisms to management

Management of acute decompensated valvular heart disease

Valvular Heart Interventions: Advances From 2019 To 2020

The Global Burden of Valvular Heart Disease: From Clinical Epidemiology to Management

Valvular Heart Interventions: Advances from 2019 to 2020.

Valvular aspects of rheumatic heart disease

Unraveling the Mechanisms of Valvular Heart Disease to Identify Medical Therapy Targets: A Scientific Statement From the American Heart Association

Current Status and Challenges of Valvular Heart Disease Interventional Therapy

Demographics and mortality trends of valvular heart disease in older adults in the United States: Insights from CDC-wonder database 1999-2019

Advancing strategies for valvular heart disease and pulmonary hypertension: insights and perspectives

A Hospital-Based Survey of Patients with Severe Valvular Heart Disease in China

Valvular Heart Disease: New Concepts in Pathophysiology and Therapeutic Approaches

Unmet needs and knowledge gaps in aortic stenosis: A position paper from the Heart Valve Council of the French Society of Cardiology

Valvular disease burden in the modern era of percutaneous and surgical interventions: the UK Biobank

Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape

Valvular Heart Disease Epidemiology

Disparities in Mitral Valve Disease Associated with Heart Failure